Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.59 |
| ▸ | JAK2 | O60674 | 5/20 | 0.59 |
| ▸ | CD69 | Q07108 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.59 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.59 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.59 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.59 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.59 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169613 | 1.00 | BTK (0.59) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL25167760 | 0.97 | BTK (0.56) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL30434245 | 0.97 | BTK (0.56) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL25170622 | 0.96 | BTK (0.56) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL31169602 | 0.96 | BTK (0.56) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL25173935 | 0.93 | BTK (0.53) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL31169600 | 0.93 | BTK (0.53) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL30434222 | 0.92 | BTK (0.55) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL25176341 | 0.92 | BTK (0.55) | BTKJAK2CD69CYP3A4HRH2 | |
| SCHEMBL25169908 | 0.91 | BTK (0.58) | BTKJAK2CD69CYP3A4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | claimed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |